User menu

Conditioning with 8-Gy total body irradiation for allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia

Bibliographic reference Ferrant, Augustin ; Van Den Neste, Eric ; Vekemans, Marie-Christiane ; Richard, Françoise ; Grégoire, Vincent ; et. al. Conditioning with 8-Gy total body irradiation for allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia.33rd Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (Lyon (France), Mar 25-28, 2007). In: Bone Marrow Transplantation, Vol. 39, p. S59-S60 (2007)
Permanent URL http://hdl.handle.net/2078.1/59664
  1. Darrington DL, J Clin Oncol, 12, 2527 (1994)
  2. Stone RM, J Clin Oncol, 12, 2535 (1994)
  3. Friedberg JW, J Clin Oncol, 17, 3128 (1999)
  4. Brown Jennifer R., Yeckes Heather, Friedberg Jonathan W., Neuberg Donna, Kim Helen, Nadler Lee M., Freedman Arnold S., Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin’s Lymphoma, 10.1200/jco.2005.05.158
  5. Miller JS, Blood, 83, 3780 (1994)
  6. Bhatia S, Blood, 87, 3633 (1996)
  7. Traweek ST, Blood, 84, 957 (1994)
  8. Krishnan A, Blood, 95, 1588 (2000)
  9. Wheeler C, Leuk Lymphoma, 40, 499 (2001)
  10. Taylor PRA, Jackson GH, Lennard AL, Hamilton PJ, Proctor SJ, Low incidence of myelodysplastic syndrome following transplantation using autologous non-cryopreserved bone marrow, 10.1038/sj.leu.2400795
  11. Andre M, Blood, 92, 1933 (1998)
  12. Milligan Donald W., Ruiz de Elvira M. Carmen, Kolb Hans-Jochem, Goldstone Anthony H., Meloni Giovanna, Rohatiner Ama Z., Colombat Phillip, Schmitz Norbert, Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT, 10.1046/j.1365-2141.1999.01627.x
  13. Harrison C N, Gregory W, Hudson G Vaughan, Devereux S, Goldstone A H, Hancock B, Winfield D, MacMillan A K, Hoskin P, Newland A C, Milligan D, Linch D C, High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin’s disease is unlikely to be associated with a major increased risk of secondary MDS/AML, 10.1038/sj.bjc.6690718
  14. Micallef IN, J Clin Oncol, 18, 947 (2000)
  15. Park S, Brice P, Noguerra M E, Simon D, Rousselot P, Kerneis Y, Morel P, Marolleau J P, Gisselbrecht C, Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies, 10.1038/sj.bmt.1702510
  16. Sureda A, J Clin Oncol, 19, 1395 (2001)
  17. Hosing C., Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma, 10.1093/annonc/mdf109
  18. Sevilla J., Rodríguez A., Hernández-Maraver D., de Bustos J., Aguado M., Ojeda E., Arrieta R., Hernández-Navarro F., Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation, 10.1007/s00277-001-0400-0
  19. Beauchamp-Nicoud Anne, Feneux Danielle, Bayle Chantal, Bernheim Alain, Léonard Claude, Koscielny Serge, Tchernia Gil, Bourhis Jean-Henri, Therapy-related myelodysplasia and/or acute myeloid leukaemia after autologous haematopoietic progenitor cell transplantation in a prospective single centre cohort of 221 patients : tMDS/tAML after ASCT, 10.1046/j.1365-2141.2003.04388.x
  20. Metayer C., Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study, 10.1182/blood-2002-04-1261
  21. Schouten Harry C., Qian Wendi, Kvaloy Stein, Porcellini Adolfo, Hagberg Hans, Johnsen Hans Erik, Doorduijn Jeanette K., Sydes Matthew R., Kvalheim Gunnar, High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP Trial, 10.1200/jco.2003.10.023
  22. Lenz Georg, Dreyling Martin, Schiegnitz Eva, Haferlach Torsten, Hasford Joerg, Unterhalt Michael, Hiddemann Wolfgang, Moderate Increase of Secondary Hematologic Malignancies After Myeloablative Radiochemotherapy and Autologous Stem-Cell Transplantation in Patients With Indolent Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group, 10.1200/jco.2004.06.016
  23. Deconinck E., High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS, 10.1182/blood-2004-10-3920
  24. Forrest Donna L., Hogge Donna E., Nevill Thomas J., Nantel Stephen H., Barnett Michael J., Shepherd John D., Sutherland Heather J., Toze Cynthia L., Smith Clayton A., Lavoie Julye C., Song Kevin W., Voss Nicholas J., Gascoyne Randy D., Connors Joseph M., High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation, 10.1200/jco.2005.01.9083
  25. Kalaycio Matt, Rybicki Lisa, Pohlman Brad, Sobecks Ronald, Andresen Steven, Kuczkowski Elizabeth, Bolwell Brian, Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia, 10.1200/jco.2006.06.0673
  26. Sebban C., Mounier N., Brousse N., Belanger C., Brice P., Haioun C., Tilly H., Feugier P., Bouabdallah R., Doyen C., Salles G., Coiffier B., Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA), 10.1182/blood-2006-03-013193
  27. Ladetto M, Vallet S, Benedetti F, Vitolo U, Martelli M, Callea V, Patti C, Coser P, Perrotti A, Sorio M, Boccomini C, Pulsoni A, Stelitano C, Scimè R, Boccadoro M, Rosato R, De Marco F, Zanni M, Corradini P, Tarella C, Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial, 10.1038/sj.leu.2404346
  28. Larson RA, Chem Biol Interact, 153–, 187 (2005)
  29. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T, Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML, 10.1038/sj.leu.2403187
  30. Leone G, Haematologica, 84, 937 (1999)
  31. Bloomfield Clara D., Archer Kellie J., Mrózek Krzysztof, Lillington Debra M., Kaneko Yasuhiko, Head David R., Dal Cin Paola, Raimondi Susana C., 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: Report from an International Workshop† : Balanced 11q23 Aberrations in t-MDS/t-AL, 10.1002/gcc.10046
  32. Davies Stella M., Therapy-related leukemia associated with alkylating agents, 10.1002/mpo.1126
  33. Josting Andreas, Wiedenmann Sabine, Franklin Jeremy, May Michael, Sieber Markus, Wolf Juergen, Engert Andreas, Diehl Volker, Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin’s Disease: A Report From the German Hodgkin’s Lymphoma Study Group, 10.1200/jco.2003.07.160
  34. Witherspoon RP, J Clin Oncol, 19, 2134 (2001)
  35. Yakoub-Agha I, J Clin Oncol, 18, 963 (2000)
  36. Delwail Vincent, Jais Jean-Philippe, Colonna Pierre, Andrieu Jean-Marie, Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation, 10.1046/j.1365-2141.2002.03564.x
  37. Schonfeld SJ, J Natl Cancer Inst, 98, 215 (2006)
  38. Andrieu JM, J Clin Oncol, 8, 1148 (1990)
  39. Mauch PM, Blood, 87, 3625 (1996)
  40. Munker R., Grützner S., Hiller E., Aydemir Ü., Enne W., Dietzfelbinger H., Busch M., Haas R., Emmerich B., Schmidt M., Dühmke E., Hölzel D., Wilmanns W., Second malignancies after Hodgkin's disease: the Munich experience, 10.1007/s002770050556
  41. Pedersen-Bjergaard J, Lancet, 2, 83 (1987)
  42. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, Vaughan Hudson B, MacLennan KA, Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease and splenectomy, 10.1038/bjc.1993.470
  43. Tucker MA, N Engl J Med, 318, 76 (1988)
  44. van Leeuwen FE, J Clin Oncol, 12, 1063 (1994)
  45. Travis L. B., Curtis R. E., Stovall M., Holowaty E. J., van Leeuwen F. E., Glimelius B., Lynch C. F., Hagenbeek A., Li C.-Y., Banks P. M., Gospodarowicz M. K., Adami J., Wacholder S., Inskip P. D., Tucker M. A., Boice J. D., Risk of Leukemia Following Treatment for Non-Hodgkin's Lymphoma, 10.1093/jnci/86.19.1450
  46. Andre M., Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients, 10.1182/blood-2003-04-1124
  47. Mudie Nadejda Y., Swerdlow Anthony J., Higgins Craig D., Smith Paul, Qiao Zongkai, Hancock Barry W., Hoskin Peter J., Linch David C., Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort Study, 10.1200/jco.2005.04.2200
  48. Armitage James O., Carbone Paul P., Connors Joseph M., Levine Alexandra, Bennett John M., Kroll Stewart, Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma Patients, 10.1200/jco.2003.07.113
  49. Kröger N, Damon L, Zander A R, Wandt H, Derigs G, Ferrante P, Demirer T, Rosti G, Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients, 10.1038/sj.bmt.1704291
  50. Rodenhuis Sjoerd, Bontenbal Marijke, Beex Louk V.A.M., Wagstaff John, Richel Dick J., Nooij Marianne A., Voest Emile E., Hupperets Pierre, van Tinteren Harm, Peterse Hans L., TenVergert Elisabeth M., de Vries Elisabeth G.E., High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer, 10.1056/nejmoa022794
  51. Govindarajan Rangaswamy, Jagannath Sundar, Flick James T., Vesole David H., Sawyer Jeffrey, Barlogie Bart, Tricot Guido, Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma, 10.1046/j.1365-2141.1996.d01-1891.x
  52. Kollmannsberger Christian, Hartmann J�rg T., Kanz Lothar, Bokemeyer Carsten, Therapy-related malignancies following treatment of germ cell cancer, 10.1002/(sici)1097-0215(19991210)83:6<860::aid-ijc32>3.0.co;2-l
  53. Abruzzese E, Blood, 94, 1814 (1999)
  54. Lillington DM, J Clin Oncol, 19, 2472 (2001)
  55. Mach-Pascual S, Blood, 91, 4496 (1998)
  56. Sharpless Norman E., DePinho Ronald A., Telomeres, stem cells, senescence, and cancer, 10.1172/jci200420761
  57. Bhatia Ravi, Van Heijzen Khristine, Palmer Ann, Komiya Asako, Slovak Marilyn L., Chang Karen L., Fung Henry, Krishnan Amrita, Molina Arturo, Nademanee Auayporn, O'Donnell Margaret, Popplewell Leslie, Rodriguez Roberto, Forman Stephen J., Bhatia Smita, Longitudinal Assessment of Hematopoietic Abnormalities After Autologous Hematopoietic Cell Transplantation for Lymphoma, 10.1200/jco.2005.10.330
  58. Thornley I., Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss, 10.1182/blood.v99.7.2387
  59. Gisselbrecht Christian, Lepage Eric, Molina Thierry, Quesnel Bruno, Fillet Georges, Lederlin Pierre, Coiffier Bertrand, Tilly Hervé, Gabarre Jean, Guilmin Francoise, Hermine Olivier, Reyes Félix, Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma, 10.1200/jco.2002.02.125
  60. Haioun C, J Clin Oncol, 18, 3025 (2000)
  61. Kaiser Ulrich, Uebelacker Irmgard, Abel Ulrich, Birkmann Josef, Trumper Lorenz, Schmalenberg Harald, Karakas Tunca, Metzner Bernd, Hossfeld Dieter K., Bischoff Helge G., Franke Astrid, Reiser Marcel, Muller Peter, Mantovani Luisa, Grundeis Marc, Rothmann Frank, von Seydewitz Cay-Uwe, Mesters Rolf M., Steinhauer Ernst U., Krahl Dorothea, Schumacher Kurt, Kneba Michael, Baudis Michael, Schmitz Norbert, Pfab Rudiger, Koppler Hubert, Parwaresch Reza, Pfreundschuh Michael, Havemann Klaus, Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” Lymphoma, 10.1200/jco.2002.07.075
  62. Martelli Maurizio, Gherlinzoni Filippo, De Renzo Amalia, Zinzani Pier Luigi, De Vivo Antonio, Cantonetti Maria, Falini Brunangelo, Storti Sergio, Meloni Giovanna, Rizzo Manuela, Molinari Anna Lia, Lauria Francesco, Moretti Luciano, Lauta Vito Michele, Mazza Patrizio, Guardigni Luciano, Pescarmona E., Pileri S.A., Mandelli Franco, Tura Sante, Early Autologous Stem-Cell Transplantation Versus Conventional Chemotherapy as Front-Line Therapy in High-Risk, Aggressive Non-Hodgkin’s Lymphoma: An Italian Multicenter Randomized Trial, 10.1200/jco.2003.01.117
  63. Milpied Noel, Deconinck Eric, Gaillard Fanny, Delwail Vincent, Foussard Charles, Berthou Christian, Gressin Remy, Lucas Virginie, Colombat Philippe, Harousseau Jean-Luc, Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support, 10.1056/nejmoa031770
  64. Santini G, J Clin Oncol, 16, 2796 (1998)
  65. Vitolo U, Haematologica, 90, 793 (2005)
  66. Philip Thierry, Guglielmi Cesare, Hagenbeek Anton, Somers Renier, Van Der Lelie Hans, Bron Dominique, Sonneveld Pieter, Gisselbrecht Christian, Cahn Jean-Yves, Harousseau Jean-Luc, Coiffier Bertrand, Biron Pierre, Mandelli Franco, Chauvin Franck, Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma, 10.1056/nejm199512073332305
  67. Gilliland D.Gary, Molecular genetics of human leukemias: New insights into therapy, 10.1053/shem.2002.36921
  68. Marcucci Guido, Mr??zek Krzysztof, Bloomfield Clara D, Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics : , 10.1097/01.moh.0000149608.29685.d1
  69. Smith Matthew L., Cavenagh Jamie D., Lister T. Andrew, Fitzgibbon Jude, Mutation ofCEBPAin Familial Acute Myeloid Leukemia, 10.1056/nejmoa041331
  70. Gilliland D. Gary, Song Woo-Joo, Sullivan Melanie G., Legare Robert D., Hutchings Sarah, Tan Xiaolian, Kufrin Dubravka, Ratajczak Janina, Resende Isabel C., Haworth Catherine, Hock Randy, Loh Mignon, Felix Carolyn, Roy Denis-Claude, Busque Lambert, Kurnit David, Willman Cheryl, Gewirtz Alan M., Speck Nancy A., Bushweller John H., Li Frederick P., Gardiner Katheleen, Poncz Mortimer, Maris John M., 10.1038/13793
  71. Side Lucy, Taylor Brigit, Cayouette Matthew, Conner Edward, Thompson Patricia, Luce Michael, Shannon Kevin, Homozygous Inactivation of theNF1Gene in Bone Marrow Cells from Children with Neurofibromatosis Type 1 and Malignant Myeloid Disorders, 10.1056/nejm199706123362404
  72. Hisada Michie, Garber Judy E., Li Frederick P., Fung Claire Y., Fraumeni Joseph F., Multiple Primary Cancers in Families With Li-Fraumeni Syndrome, 10.1093/jnci/90.8.606
  73. Papageorgio Chris, Seiter Karen, Feldman Eric J., Therapy-Related Myelodysplastic Syndrome in Adults with Neurofibromatosis, 10.3109/10428199909058420
  74. Knoche Eric, McLeod Howard L, Graubert Timothy A, Pharmacogenetics of alkylator-associated acute myeloid leukemia, 10.2217/14622416.7.5.719
  75. Schnittger Susanne, Kohl Tobias M., Leopold Nina, Schoch Claudia, Wichmann H.-Erich, Kern Wolfgang, Lohse Peter, Hiddemann Wolfgang, Haferlach Torsten, Spiekermann Karsten, D324N single-nucleotide polymorphism in theFLT3 gene is associated with higher risk of myeloid leukemias, 10.1002/gcc.20294
  76. Wolfler A., A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome, 10.1182/blood-2004-06-2094
  77. Christiansen D H, Andersen M K, Desta F, Pedersen-Bjergaard J, Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia, 10.1038/sj.leu.2404009
  78. Harada H., High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia, 10.1182/blood-2003-09-3074
  79. Christiansen DH, J Clin Oncol, 19, 1405 (2001)
  80. Side Lucy E., Curtiss Nicole P., Teel Kathryn, Kratz Christian, Wang Pauline W., Larson Richard A., Le Beau Michelle M., Shannon Kevin M., RAS,FLT3, andTP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7, 10.1002/gcc.10320
  81. Felix C. A., Walker A. H., Lange B. J., Williams T. M., Winick N. J., Cheung N.-K. V., Lovett B. D., Nowell P. C., Blair I. A., Rebbeck T. R., Association of CYP3A4 genotype with treatment-related leukemia, 10.1073/pnas.95.22.13176
  82. Rund D, Krichevsky S, Bar-Cohen S, Goldschmidt N, Kedmi M, Malik E, Gural A, Shafran-Tikva S, Ben-Neriah S, Ben-Yehuda D, Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients, 10.1038/sj.leu.2403947
  83. Roddam P. L., Rollinson S., Kane E., Roman E., Moorman A., Cartwright R., Morgan G. J., Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia : , 10.1097/00008571-200010000-00004
  84. Allan J. M., Wild C. P., Rollinson S., Willett E. V., Moorman A. V., Dovey G. J., Roddam P. L., Roman E., Cartwright R. A., Morgan G. J., Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia, 10.1073/pnas.191211198
  85. Naoe T, Clin Cancer Res, 6, 4091 (2000)
  86. Larson RA, Blood, 94, 803 (1999)
  87. Allan J. M., Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy, 10.1182/blood-2004-06-2161
  88. Worrillow LJ, Clin Cancer Res, 9, 3012 (2003)
  89. Seedhouse C., The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia, 10.1182/blood-2002-04-1152
  90. Roddam Philippa L., Allan James M., Rollinson Sara, Smith Alexandra G., Willett Eleanor V., Swirsky David, Roman Eve, Morgan Gareth J., Poor metabolizer status at the cytochrome p450 2c19 and 2d6 loci does not modulate susceptibility to therapy-related acute myeloid leukaemia, 10.1046/j.1365-2141.2003.04245_3.x
  91. Ye Zheng, Song Honglin, Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: A systematic review and meta-analysis, 10.1016/j.ejca.2005.01.014
  92. Fenske Timothy S., McMahon Christine, Edwin Deepa, Jarvis Joseph C., Cheverud James M., Minn Matthew, Mathews Vikram, Bogue Molly A., Province Michael A., McLeod Howard L., Graubert Timothy A., Identification of Candidate Alkylator-Induced Cancer Susceptibility Genes by Whole Genome Scanning in Mice, 10.1158/0008-5472.can-05-3404
  93. Jerusalem Guy, Hustinx Roland, Beguin Yves, Fillet Georges, Evaluation of Therapy for Lymphoma, 10.1053/j.semnuclmed.2005.02.004
  94. Sehn LH, Blood, 106, 492 (2005)
  95. Lossos Izidore S., Morgensztern Daniel, Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma, 10.1200/jco.2005.02.4786
  96. Crump Michael, Baetz Tara, Couban Stephen, Belch Andrew, Marcellus Deborah, Howson-Jan Kang, Imrie Kevin, Myers Robert, Adams Grenfell, Ding Keyue, Paul Nancy, Shepherd Lois, Iglesias Jose, Meyer Ralph, Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma : A Phase II study by the National Cancer Institute of Canada Clinical Trials Group(NCIC-CTG), 10.1002/cncr.20587
  97. Baetz T., Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group, 10.1093/annonc/mdg496
  98. Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman A R, Wotherspoon A, Catovsky D, Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma, 10.1038/sj.bjc.6602514